Piet P M M Geusens

Summary

Affiliation: Limburgs Universitair Centrum
Country: Belgium

Publications

  1. ncbi The relationship among history of falls, osteoporosis, and fractures in postmenopausal women
    Piet Geusens
    Biomedical Research Institute, Limburgs Universitair Centrum, Diepenbeek, Belgium
    Arch Phys Med Rehabil 83:903-6. 2002
  2. ncbi High prevalence of thoracic vertebral deformities and discal wedging in ankylosing spondylitis patients with hyperkyphosis
    P Geusens
    Department of Rheumatology, University Hospital, University of Maastricht, The Netherlands
    J Rheumatol 28:1856-61. 2001
  3. ncbi Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis
    P Geusens
    Biomedisch Onderzoeksinstituut, Limburgs Universitair Centrum, Diepenbeek, Belgium
    Int J Clin Pract 58:1033-41. 2004
  4. ncbi Review of guidelines for testing and treatment of osteoporosis
    Piet P M M Geusens
    Biomedical Research Institute, Limburgs Universitair Centrum Belgium, Department of Rheumatology, University Hospital, P Debyelaan 25, Postbus 5800, 6202 AZ Maastricht, The Netherlands
    Curr Osteoporos Rep 1:59-65. 2003
  5. ncbi Osteoporosis and the growth hormone-insulin-like growth factor axis
    Piet P M M Geusens
    Department of Rheumatology, University Hospital, Maastricht, The Netherlands
    Horm Res 58:49-55. 2002
  6. ncbi Review of risedronate in the treatment of osteoporosis
    P Geusens
    Department of Rheumatology, University Hospital, Maastricht, The Netherlands
    Expert Opin Pharmacother 2:2011-25. 2001
  7. ncbi Recovery from severe glucocorticoid-induced osteoporosis in an adolescent boy
    P Geusens
    Biomedical Research Institute, Limburg University Centre, Diepenbeek, Belgium
    J Clin Densitom 4:389-94. 2001
  8. ncbi Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma
    A Caroline Heijckmann
    Department of Internal Medicine, Division of Endocrinology, University Hospital Maastricht, Maastricht, The Netherlands
    Eur J Endocrinol 153:23-9. 2005
  9. ncbi Performance of risk indices for identifying low bone density in postmenopausal women
    Piet Geusens
    Biomedical Research Institute, Limburg University, Diepenbeek, Belgium
    Mayo Clin Proc 77:629-37. 2002
  10. ncbi Evaluation of patients with a recent clinical fracture and osteoporosis, a multidisciplinary approach
    Bianca Dumitrescu
    Department of Internal Medicine, Subdivision of Rheumatology, University Hospital, Maastricht, The Netherlands
    BMC Musculoskelet Disord 9:109. 2008

Collaborators

Detail Information

Publications24

  1. ncbi The relationship among history of falls, osteoporosis, and fractures in postmenopausal women
    Piet Geusens
    Biomedical Research Institute, Limburgs Universitair Centrum, Diepenbeek, Belgium
    Arch Phys Med Rehabil 83:903-6. 2002
    ..To study the relative contribution of osteoporosis and falls to the occurrence of symptomatic fractures in postmenopausal women...
  2. ncbi High prevalence of thoracic vertebral deformities and discal wedging in ankylosing spondylitis patients with hyperkyphosis
    P Geusens
    Department of Rheumatology, University Hospital, University of Maastricht, The Netherlands
    J Rheumatol 28:1856-61. 2001
    ..To study the prevalence of deformities of vertebrae and intervertebral discs in patients with ankylosing spondylitis (AS) in relation to fixed hyperkyphosis of the spine...
  3. ncbi Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis
    P Geusens
    Biomedisch Onderzoeksinstituut, Limburgs Universitair Centrum, Diepenbeek, Belgium
    Int J Clin Pract 58:1033-41. 2004
    ..Prespecified gastrointestinal adverse events were more frequent with naproxen than with either lumiracoxib dose or placebo. Lumiracoxib is therefore an effective and well-tolerated therapy for RA...
  4. ncbi Review of guidelines for testing and treatment of osteoporosis
    Piet P M M Geusens
    Biomedical Research Institute, Limburgs Universitair Centrum Belgium, Department of Rheumatology, University Hospital, P Debyelaan 25, Postbus 5800, 6202 AZ Maastricht, The Netherlands
    Curr Osteoporos Rep 1:59-65. 2003
    ..Consistent recommendations are found mostly for raloxifene in the prevention of vertebral fractures and for alendronate and risedronate in the prevention of vertebral and nonvertebral fractures, including hip fractures...
  5. ncbi Osteoporosis and the growth hormone-insulin-like growth factor axis
    Piet P M M Geusens
    Department of Rheumatology, University Hospital, Maastricht, The Netherlands
    Horm Res 58:49-55. 2002
    ..We will review the evidence of GH and IGF-I in the pathophysiology and treatment of osteoporosis...
  6. ncbi Review of risedronate in the treatment of osteoporosis
    P Geusens
    Department of Rheumatology, University Hospital, Maastricht, The Netherlands
    Expert Opin Pharmacother 2:2011-25. 2001
    ..There was no evidence of acute-phase reactions or primary mineralisation defects. The most appropriate dose of risedronate was 5 mg/day...
  7. ncbi Recovery from severe glucocorticoid-induced osteoporosis in an adolescent boy
    P Geusens
    Biomedical Research Institute, Limburg University Centre, Diepenbeek, Belgium
    J Clin Densitom 4:389-94. 2001
    ..This case proves that treatment of symptomatic glucocorticoid-induced osteoporosis during puberty can be rewarding, even when multiple and invalidating vertebral fractures already exist...
  8. ncbi Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma
    A Caroline Heijckmann
    Department of Internal Medicine, Division of Endocrinology, University Hospital Maastricht, Maastricht, The Netherlands
    Eur J Endocrinol 153:23-9. 2005
    ..However, their effect on bone turnover, their contribution to bone mineral density (BMD) in the context of other clinical risk factors for osteoporosis and the prevalence of vertebral fractures is not well documented...
  9. ncbi Performance of risk indices for identifying low bone density in postmenopausal women
    Piet Geusens
    Biomedical Research Institute, Limburg University, Diepenbeek, Belgium
    Mayo Clin Proc 77:629-37. 2002
    ..The Osteoporosis Self-assessment Tool index is easiest to calculate and therefore may be most useful in clinical practice...
  10. ncbi Evaluation of patients with a recent clinical fracture and osteoporosis, a multidisciplinary approach
    Bianca Dumitrescu
    Department of Internal Medicine, Subdivision of Rheumatology, University Hospital, Maastricht, The Netherlands
    BMC Musculoskelet Disord 9:109. 2008
    ..Identifying and correcting these associated disorders will enhance treatment effect aimed at reducing the risk of subsequent fractures in patients older than 50 years...
  11. ncbi Fracture prevention in men
    Piet Geusens
    Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
    Nat Rev Rheumatol 5:497-504. 2009
    ..For men with severe osteoporosis, treatment with the anabolic agent teriparatide might be an effective option...
  12. ncbi Integrating a gender dimension into osteoporosis and fracture risk research
    Piet Geusens
    Department of Internal Medicine Rheumatology, University Hospital, Maastricht, The Netherlands
    Gend Med 4:S147-61. 2007
    ..Sex (referring to the strict biological sense) and gender (referring to the sociocultural dimension) are major determinants of health and disease...
  13. ncbi Risk of new clinical fractures within 2 years following a fracture
    Svenhjalmar van Helden
    Department of Trauma Surgery, Academic Hospital Maastricht, P Debijelaan 25, Postal number 5800, 6202 AZ, Maastricht, The Netherlands
    Osteoporos Int 17:348-54. 2006
    ..The study objective was to determine the absolute risk of subsequent clinical fractures within 2 years after a clinical fracture...
  14. ncbi Newer drug treatments: their effects on fracture prevention
    Piet Geusens
    Biomedical Research Institute, University Hasselt, Campus Diepenbeek, Belgium
    Best Pract Res Clin Rheumatol 19:983-9. 2005
    ..Some new drugs that are being studied for their potential anti-fracture effects are listed...
  15. ncbi Factors affecting bone loss in female endurance athletes: a two-year follow-up study
    Lavienja A J L M Braam
    Department of Biochemistry, University of Maastricht, Maastricht, The Netherlands
    Am J Sports Med 31:889-95. 2003
    ..Clinical Relevance: High-intensity training maintained over several years must be regarded in women as a risk factor for osteoporosis, and protocols for optimal treatment should be developed...
  16. ncbi Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial
    Debby den Uyl
    Department of Rheumatology, VU Medical Centre, Room 3A58, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    Clin Rheumatol 29:465-72. 2010
    ..A significant greater number of patients considered the chewable tablet as preferable and acceptable to the sachet, containing calcium and vitamin D(3). TRIAL REGISTRATION: Current Controlled Trials ISRCTN18822358...
  17. ncbi [Should the vitamin D level be determined for all fracture patients?]
    Joop van den Bergh
    Universitair Medisch Centrum Maastricht, afd Interne Geneeskunde, subdivisie Endocrinologie, Maastricht, The Netherlands
    Ned Tijdschr Geneeskd 154:A1758. 2010
    ....
  18. ncbi The fracture and osteoporosis outpatient clinic: an effective strategy for improving implementation of an osteoporosis guideline
    Svenhjalmar van Helden
    Department of General Surgery, Academic Hospital of Maastricht, Maastricht, The Netherlands
    J Eval Clin Pract 13:801-5. 2007
    ....
  19. ncbi Falls and fractures in postmenopausal women: a review
    Piet Geusens
    Biomedical Research Institute, Limburgs Universitair Centrum, Diepenbeek, Belgium
    J Br Menopause Soc 9:101-6. 2003
    ..Prospective studies are needed to evaluate whether a combined bone- and fall-directed therapy can further decrease the risk for fractures in patients with low bone density and an increased fall risk...
  20. ncbi Strategies for treatment to prevent fragility fractures in postmenopausal women
    Piet Geusens
    Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
    Best Pract Res Clin Rheumatol 23:727-40. 2009
    ..Follow-up allows to check tolerance and safety, to optimise adherence and to decide about adequacy of response, duration and switching of therapy...
  21. ncbi Emerging treatments for postmenopausal osteoporosis - focus on denosumab
    Piet Geusens
    Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
    Clin Interv Aging 4:241-50. 2009
    ....
  22. ncbi Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis
    Ron N J de Nijs
    Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
    N Engl J Med 355:675-84. 2006
    ..Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture...
  23. ncbi Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis
    Johannes W G Jacobs
    Department of Rheumatology and Clinical Immunology and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
    J Rheumatol 34:1051-7. 2007
    ....
  24. ncbi Osteoporosis in men
    Willem F Lems
    N Engl J Med 359:868; author reply 869. 2008